

[Pyridostigmine](#)

Essential medicine status

Section:

[5. Medicines for neurological disorders](#) [5.2. Medicines for peripheral nervous system disorders](#) [5.2.2. Medicines for myasthenia gravis](#)

ATC codes: [N07AA02](#)

EMLc

Indication

Myasthenia gravis ICD11 code: [8C70.Z](#)

INN

Pyridostigmine bromide

Medicine type

Chemical agent

List type

Complementary

Formulations

Parenteral > General injections > IV: 5 mg per mL in ampoule or vial (pyridostigmine bromide)

Oral > Solid > tablet: 60 mg scored (pyridostigmine bromide)

EML status history

First added in 1977 ([TRS 615](#))

Changed in 1979 ([TRS 641](#))

Changed in 1993 ([TRS 850](#))

Changed in 2003 ([TRS 920](#))

Changed in 2007 ([TRS 950](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Pyridostigmine](#)

DrugBank

[Pyridostigmine](#)

Summary of evidence and Expert Committee recommendations

Listings for medicines for treatment of myasthenia gravis are duplicated in this section from section 20.